You know, when I saw “who would have believed this,” I knew exactly who would have seen it coming, @ASrinivasan. You were saying this before anyone else.
The rest of us, not so much
You know, when I saw “who would have believed this,” I knew exactly who would have seen it coming, @ASrinivasan. You were saying this before anyone else.
The rest of us, not so much
LOL! Jason,
I didn’t see this tsunami coming, though
I never thought the day would come when we would have to be careful about even trace amounts of nitrous acid in the air. Even though secondary amines are said to be highly reactive, I thought that this only applied to homogeneous solutions…
Nice observation!
It feels like everything was just about an amine and a nitrite and we had no idea!
I never imagined I would get to experience medicinal/organic chemistry and toxicology in such a hands-on way, directly through real-world scenarios.
It’s also wonderful to see scientific knowledge being shared with people from all around the world. Huge thanks to the community for making these exchanges possible.
I’m truly happy to have met Yosuke, Naiffer, and so many others.
Great question — and what a journey it’s been!
Looking back, one thing I wish I had known earlier is just how nuanced and complex the analytical challenges around nitrosamines truly are. There’s often a misconception that it’s just about developing a sensitive method and ticking a regulatory box. But in reality, it demands a deep understanding of chemistry, instrumentation and risk assessment.
For example, achieving the required sensitivity isn’t just about choosing the “right” LC-MS method — it’s about optimizing every detail: sample prep, injection volume, matrix effect mitigation, and even how you handle your solvents and labware. And then there’s the constant challenge of artifact formation during sample prep or storage — something I wish more people talked about openly.
I’ve learned there are no one-size-fits-all solutions. So my biggest takeaway is this: expertise matters — and we’re all still learning, together.
I completely agree, Lucas. I am shocked that instrument manufacturers have not been recording record sales.
If only I had know…
NOx in ambient air is a nitrosation source.
That there are several pharma unit ops which use large amounts of ambient air in direct contact with the drug product including fluid bed drying and tablet coating.
There are reports of very reactive 2ry amines undergoing nitrosation if just left in ambient air in the laboratory.
dear Hermine
could you please share your opinion on how we should monitor the NOx limits in the mentioned facilities? is there any acceptable approach from authorities? any frequency etc?
BR
I am a pharmacist by training. I’ve been working with nitrosamines.
I couldn’t agree more!
Dear Eleni Politi, WO2025/004104A1 recommends using ionized air, becouse in several pharma unit ops which use large amounts of ambient air in direct contact with the drug product including fluid bed drying and tablet coating, risk Nox is very high. NDSRI content of the active pharmaceutical ingredients before and after exposure to the ionized air is different, after exposure to the ionized air concentration NDSRI lower, see below link. However, in guidelines I didn’t see any mentions about NOx.
I participated in Genotoxic, nitrosamine beyond (online) too and I asked this question to speaker (You participated too, YES?). I think I was able to be helpful.
Can Ionized Air in Pharma Pose a Risk of Nitrite Formation.pdf (926.1 KB)
dear Hermine,
indeed it was a really informative summit thanks to great speakers!
As for NOx, EFPIA includes discussion on their potential contribution in nitrosamines formation (minor contributors). What’s more I trust, that air quality should be covered by GMP assessment.
Whats more, what it was discussed during the summit was that significant increase of nitrosamines due to air NOx has not been observed in industrial/ production scale, rather than small scale (plate) experiments.
I am sure that other colleagues join the USP NF have also attended the 9th Genotoxic, nitrosamine and beyond summit, so please share any additional feedback.
thank you
@schlinjo1975 do you have any insight? I know you and the team have been looking carefully at this
Dear @elenipoliti
Very interesting to hear that it was thought that NOx in the atmosphere was not a significant contributor to nitrosamine formation.
From my reading on the subject of nitrosamines over the past few years I find this a surprising position to reach, for a variety of reasons.
I would have thought that it might be easier for the level of NOx to increase on the factory scale, and be more difficult to reproduce on the smaller lab or pilot scale. The temperatures, volumes of air, and times required for drying a full scale batch may be such that there is the opportunity for the creation of NOx to then be absorbed by the product. The same potentially also true for spray coating, where there is also moisture involved, but maybe less so for the milling process, which is quicker, and drier.
I think that there is also some empirical data that has been presented previously that shows the levels of nitrosamine formed through the different stages of manufacture of a product, and where there are increases in the observed levels (fluid bed drying etc.) - but whether this is due to just the increase in temperature of those stages, or the presence of NOx has not been presented to date. However, I think that the patent included earlier in this thread indicates that the ionization of the air leads to a decrease in the levels of nitrosamine observed, which would suggest NOx as at least a significant cause, rather than just the heat and nitrites present in materials initially.
I would caveat all of this with the observation that every manufacturing process of every product, with different APIs, to form different nitrosamines behaves differently - and not always in a way that is predictable, unfortunately. What may be true for one product may not always be true for another.
thank you for this detailed feedback. please don’t get me wrong. Perhaps I am mistaken too regarding what it was discussed during summit, and that’s why I called for further feedback .
However, I agree with point 3 for the study completed in Japan, but it referred to pollutant areas.
From my experience, quality of the compressed air, at the points of use that the air is going to be in contact with product, must conform with the requirements defined by the European Pharmacopeia as well as with the GMP requirements; oxides of nitrogen: NMT 2ppm.
however, as you said what works for one product may not work for another, so, perhaps this limit is high for other products, and I will note the “heads up”.
BR